klmline Posted November 17, 2006 Share Posted November 17, 2006 Here's the link: http://www.targetedtherapies.org/rdt1_5.html -click on the hyperlink to launch presentation Let's Review Dr. Butts presentation. Slide 16 Final Analysis The vaccine arm: 11/2005 survival data at 30.6 months, median survival milestone is reached (18 deaths=51%). Looks like a death at 46 months and another at 53 months Stage IIIB subgroup n=65 vaccine arm = 35 patients, Control arm = 30 Looks like 14 of the 35 patients (40%)in the vaccine are are still alive at 64 months.....WOW! The actual survival calculation was in fact better because survival was calculated at the start of randomization. The true baseline can be argued to be at the actual beginning of therapy!......WOW! Study might be optomized futher with repeated use of cyclophosamide!.....WOW! P value was actually .049 at end of study.....WOW! EXTRA BONUS: Stage IIIA is included in protocol, IV excluded, 3 month window on randomization. Gender balance more evenly weighted in phase III......WOW Why won't the FDA allow patients access to this Drug when it has shown in every trial to be perfectly safe with little or no side affects???????????????? Those who are suffering deserve access on a humanitarian basis. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.